Clinical Trials Logo

Restless Legs Syndrome clinical trials

View clinical trials related to Restless Legs Syndrome.

Filter by:

NCT ID: NCT00314860 Completed - Clinical trials for Restless Legs Syndrome

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Start date: February 2006
Phase: Phase 3
Study type: Interventional

Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks

NCT ID: NCT00311363 Completed - Clinical trials for Restless Legs Syndrome

Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome.

Start date: April 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assess the maintenance of efficacy of gabapentin enacarbil (GEn, XP13512) taken once daily in the long-term treatment of patients suffering from Restless Legs Syndrome (RLS).

NCT ID: NCT00298623 Completed - Clinical trials for Restless Legs Syndrome

XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to assess the efficacy of XP13512 taken once daily compared to placebo for the treatment of patients suffering from Restless Legs Syndrome (RLS).

NCT ID: NCT00275457 Completed - Clinical trials for Restless Legs Syndrome

Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients

Start date: October 2002
Phase: Phase 3
Study type: Interventional

To evaluate safety and efficacy of pramipexole in the treatment of patients suffering from moderate to severe RLS over 6 weeks under double blinded conditions followed by a 46 week open label or double blind extension.

NCT ID: NCT00275236 Completed - Clinical trials for Restless Legs Syndrome

A Sleep Lab Trial to Investigate the Efficacy and Safety of Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

Start date: November 2005
Phase: Phase 3
Study type: Interventional

The objective of this trial is to demonstrate that rotigotine (SPM 936) is effective in subjects with idiopathic RLS based on the PLMI (Periodic Limb Movements Index)(PLMs/total time in bed) as measured by polysomnography (PSG). The primary variable is the reduction of PLMI at the end of the Maintenance Period compared to Baseline. PLMI data will be obtained from PSGs.

NCT ID: NCT00263068 Completed - Clinical trials for Restless Legs Syndrome

An Extension Trial to Investigate Long-Term Treatment With Transdermal Rotigotine in Idiopathic Restless Legs Syndrome

Start date: December 2005
Phase: Phase 3
Study type: Interventional

This is a multicenter, open-label trial to assess safety and tolerability of rotigotine (SPM 936) in subjects with idiopathic Restless Legs Syndrome (RLS), administered at an optimal dose for up to 1 year. Subjects who successfully completed the Maintenance Period and the Taper Period of SP792 are allowed to enroll in this trial. All subjects will begin the Titration Period at a daily dosage of 1.125mg rotigotine (2.5cm2 patch). Subjects will be up-titrated at 7-day intervals in 1.125mg (2.5cm2 increments, initial titration step only) and 2.25mg intervals (5cm2) increments to a maximum dose of 6.75mg/day (15cm2) rotigotine. The maximum length of titration is 28 days (±3 days), although not all subjects will require 28 days to reach their optimal dose. A subject's dose may be increased or decreased, as needed by the investigator to maintain a subject's effective dose during the Maintenance Period. A Taper Period is provided to allow for safe, gradual withdrawal from trial medication

NCT ID: NCT00258492 Active, not recruiting - Insomnia Clinical Trials

Restless Legs Syndrome Exercise Intervention

Start date: December 2005
Phase: Phase 1/Phase 2
Study type: Interventional

A pilot study of an aerobic exercise intervention to moderate symptoms and improve sleep quality among patients with Restless Legs Syndrome (RLS). We, the researchers at Northeastern Ohio Universities College of Medicine, hypothesize that, relative to a control group, RLS sufferers who participate in an aerobic exercise intervention will demonstrate: 1. reduced RLS symptoms; 2. improved sleep quality; 3. reduced daytime sleepiness.

NCT ID: NCT00256854 Completed - Clinical trials for Restless Legs Syndrome

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

Start date: November 14, 2005
Phase: Phase 3
Study type: Interventional

This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.

NCT ID: NCT00247364 Completed - Clinical trials for Restless Legs Syndrome

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

Start date: November 2003
Phase: Phase 2
Study type: Interventional

To define the effective dose and tolerability of levetiracetam in individuals with Restless Legs Syndrome (RLS). It is hypothesized that levetiracetam will be well tolerated, safe and effective in treating the symptoms of RLS.

NCT ID: NCT00246051 Completed - Clinical trials for Sleep Apnea, Obstructive

Comprehensive Police Fatigue Management Program

Start date: November 2005
Phase: N/A
Study type: Interventional

Police officers work some of the most demanding schedules known, which increases their risk of sleep deprivation and sleep disorders. The need to work frequent overnight shifts and long work weeks leads to acute and chronic partial sleep deprivation as well as misalignment of circadian phase. The public expects officers to perform flawlessly, but sleep deprivation and unrecognized sleep disorders significantly degrade cognition, alertness, reaction time and performance. In addition, both acute and chronic sleep deprivation adversely affect personal health, increasing the risk of gastrointestinal and heart disease, impairing glucose metabolism, and substantially increasing the risk of injury due to motor vehicle crashes. We propose to conduct a randomized, prospective study of the effect on the safety, health, and performance of a police department of a Comprehensive Police Fatigue Management Program (CPFMP) consisting of the following interventions: 1. identification and treatment of police with sleep disorders; 2. caffeine re-education; and 3. initiation of a sleep, health and safety educational program. These interventions were chosen because we believe them most likely to lead to measurable improvements on work hours, health, safety, and job performance, and because they are cost effective. The success of the CPFMP will be assessed through an experimental comparison with a standard treatment group that will receive sleep education in the absence of any accompanying interventions. The overall goal of our team will be sleep health detection and treatment program that can be disseminated to practitioners, policymakers and researchers nationwide to reduce police officer fatigue and stress; enhance the ability of officers to cope with shift schedules; improve the health, safety and performance of law enforcement officers; and thereby improve public safety.